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Objectives

Results

Discussion & Next Steps

• This study aimed to examine the experiences of parents and
caregivers of autistic children who used medical cannabis (MMJ) for
the treatment of core symptoms or co-occurring conditions

• N=50 participants

• Families of autistic children who have challenges with behavior and
communication face significant barriers to finding treatment plans
that work for them

• N=18 reported having a child with severe autism
• N=13 reported having a child with moderate autism

• Considered priorities and outcomes of medical cannabis use,
including:
• Quality of life (QoL) effects
• Symptoms of interest
• Symptoms of co-occurring conditions

ASD

MMJ

Medical marijuana (MMJ): In many U.S. states, MMJ is
an approved treatment for specific conditions, which in
some cases includes ASD.

• MMJ is rising rapidly in popularity as a potential option

• Irritability was the #1 symptom parents reporting to treat with
medical cannabis

Background
Autism spectrum disorder (ASD): A developmental
condition that can impact communication, behavior, and
social interaction. At present, 1 in 44 children in the U.S.
receives a diagnosis of ASD by age 8.

• QoL is a major concern, both for autistic children and for their
families

• Majority of respondents seeking to treat 1+ symptom with medical
cannabis

• It is clear from the literature that whether providers feel capable to
discuss the topic or not, autistic individuals and families will
continue to pursue MMJ as a possible complementary treatment

Table 1: Symptoms interested in treating with medical
cannabis
Symptom Interested In Treating
Anxiety
Irritability
Meltdowns
Obsessive Compulsiveness
Focus and Attention / ADHD
Hyperactivity
Insomnia
Self-Injurious Behaviors
Self-Stimulatory Behaviors
Communication
Other

• Research on MMJ is progressing, but legal barriers mean that
progress is slow

N (50)
18
24
16
9
17
12
14
9
13
14
7

• Current research, including this study, suggests the possibility that
MMJ could have significant benefits for at least some individuals in
this population

Conclusion
• The findings of our study have important implications for clinical
practice and research
• Respondents reported using a variety of cannabis products
including THC as well as improvement in a variety of symptoms

• Existing pharmaceutical interventions for ASD have several
limitations

• Respondents generally reported improvement across symptoms

• Side effects can also be a significant issue
• MMJ has become an increasingly common type of complementary
and alternative medicine (CAM) for this population

• Symptoms that at least 40% of participants reported improvement
in included aggression, irritability, meltdowns, anxiety, agitation,
and communication

• No respondents reported worsening of existing symptoms

• Further understanding of which cannabis products relieve which
symptoms is needed to inform future research as well as clinical
practice

• ASD is a qualifying condition for MMJ in 14 US states
• It can also be recommended at the clinician’s discretion in
some others
• Existing research has established the potential for medical cannabis
to address core symptoms, co-occurring conditions, and improve
quality of life for autistic individuals
• Evidence is limited and more research is needed

Table 2: Change in symptoms observed following initiation
of medical cannabis
Symptom
Significantly
Improved
N (%)
Total
(N=50)

Anxiety

OCD

Focus/
ADHD

Communication

GI
Issues

Insomnia

Self Stim
Behavior

Hyperactivity

22 (44)

13
(26)

15
(30)

20 (40)

11
(22)

13 (26)

12 (24)

14 (28)

10
(20)

4 (8)

6 (12)

6
(12)

5 (10)

1 (20)

3 (6)

11 (22)

10 (20)

10 (20)

10 (20)

14 (28)

20
(40)

17
(34)

20 (40)

19
(38)

11 (22)

12 (24)

12 (24)

Aggression Irritability Meltdowns

24 (48)

30 (60)

Improved N
(%)

6 (12)

7 (14)

No Change N
(%)

11 (22)

7 (14)

26 (52)

Pain

Appetite

Rage

Agitation

• Survey was provided by Hope Grows for Autism, a Pennsylvaniabased cannabis medicine group dedicated to research, education,
and advocacy supporting families with children who have autism.
• Asked about side effects, products used, effect on various symptoms,
discontinuation of medical cannabis, and other self-reported clinical
outcomes
• All data was self-reported by parents and caregivers

Self
Injury

9 (18)

15
(30)

0 (0)

5 (10)

4 (8)

8 (16)

4 (8)

10
(20)

18 (36)

10
(20)

9 (18)

6 (12)

20 (40)

17 (34)
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Methods
• Secondary analysis of a cross-sectional online survey of patients and
caregivers of children with a diagnosis of ASD and who had used
MMJ to treat symptoms
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